drugset / Trial / NCT00105040

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

NCT00105040

Phase 2 Completed 87 enrolled UCB Pharma
RandomizedParallel-groupTriple-blindTreatment

Summary

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.

Timeline

Start
2004-09
Primary completion
2007-03
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 20 mg/kg Oral
Subject Levetiracetam Other / unclassified 60 mg/kg Oral

Indications